Article

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada.
New England Journal of Medicine (Impact Factor: 54.42). 10/2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720
Source: PubMed

ABSTRACT Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease.
From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end points were pain, prostate-specific antigen (PSA) levels, and the quality of life. All statistical comparisons were against mitoxantrone.
As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test) and those given weekly docetaxel had a hazard ratio for death of 0.91 (95 percent confidence interval, 0.75 to 1.11; P=0.36). The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 months in the group given weekly docetaxel. Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel.
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone.

1 Follower
 · 
173 Views
  • OncoTargets and Therapy 01/2015; DOI:10.2147/OTT.S79776 · 1.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone metastases cause significant morbidity to patients with prostate cancer, the most commonly diagnosed solid cancer in men. In the last decade, the approach to metastatic castrate-resistant prostate cancer has evolved remarkably, with approval of multiple new medications with survival benefit. We review the radiobiology and phases of development of 223Ra (radium), an α-emitter radiopharmaceutical, and discuss the clinical implications of its use and its future role in the treatment of prostate cancer. A review of the literature was performed through searches of PubMed and Medline databases and related links in these databases, along with recently published abstracts from major medical meetings. 223Ra is an α-emitter, with high affinity to areas of bone metastases. α-Particles have high energy and short range, causing cytotoxicity to targeted cancer cells without affecting surrounding normal tissues. It has been proven to prolong overall survival, delay symptomatic skeletal events, and improve quality of life, while having a minimal toxicity profile. 223Ra is effective and safe in the treatment of bone metastatic castration-resistant prostate cancer. Additional studies are planned to assess the efficacy of 223Ra in combination with other agents known to be active in advanced prostate cancer.
    01/2015; DOI:10.1007/s40336-015-0103-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND. Prostate carcinomas are androgen-dependent neoplasms which progress toward a hormone-independent phenotype during hormone-deprivation therapy. We evaluated nevirapine, a reverse transcriptase inhibitor, as a new treatment in hormone-refractory prostate carcinoma cells with the aim of restoring the androgen-dependency of tumor cells, the rationale being that endogenous reverse transcriptase is up-regulated in transformed cells and reverse transcriptase inhibitors exert a differentiating activity in human tumors. METHODS AND RESULTS. Nevirapine induced extensive reprogramming of gene expression in vitro with up-regulation of genes that might be silenced during prostate tumor progression (i.e., K18, PSA and androgen receptor) and down-regulation of genes involved in the progression toward an androgen-independent phenotype (i.e., K5, EGFR1, EGF and VEGF-A). Furthermore, nevirapine down-regulated the growth of prostate carcinoma xenografts in athymic mice and induced a differentiated phenotype in vivo with increased K18 expression. Interestingly, the drug restored androgen signaling by enhancing the ability of tumor cells to respond to dihydrotestosterone stimulation and to the antiproliferative activity of the androgen receptor blocker bicalutamide. Finally, nevirapine pretreatment increased the susceptibility of tumor cells to docetaxel, by enhancing their ability to undergo apoptosis. CONCLUSIONS. These data suggest that nevirapine may be clinically tested in human hormone-refractory prostate carcinoma to restore the susceptibility to androgen deprivation therapy or to docetaxel. Prostate
    The Prostate 01/2009; · 3.57 Impact Factor

Full-text (2 Sources)

Download
104 Downloads
Available from
May 30, 2014